Evidence for the involvement of a potential second tumor suppressor gene on chromosome 17 distinct from p53 in malignant astrocytomas.
Molecular analysis of malignant astrocytomas demonstrated three distinct groups of tumors with chromosome 17p abnormalities, which include (a) deletion of the p53 locus (17p13.1) and mutations in the remaining allele, (b) deletion of the p53 locus but no detectable mutations in the remaining allele, and (c) deletions not including the p53 locus but mutations in one of the alleles. Furthermore, deletion mapping analysis demonstrated allelic loss of genes distal to D17S28/D17S5 markers (17p13.3) in group C tumors. The loss of heterozygosity of genes on chromosome 17 without detectable mutation (group B) or deletion (group C) in the p53 gene implies the presence of a second tumor suppressor gene in the telomeric region of 17p, the homozygous functional inactivation of which may play a role, either alone or in conjunction with p53, in the initiation and/or progression of astrocytic neoplasms.
Saxena
A
A
Surgical Neurology Branch, National Institute of Neurological Disorder and Stroke, NIH, Bethesda, Maryland 20892.
Clark
W C
WC
Robertson
J T
JT
Ikejiri
B
B
Oldfield
E H
EH
Ali
I U
IU
D001483:Base Sequence; D001932:Brain Neoplasms / Q000235:genetics*; D002886:Chromosomes, Human, Pair 17; D004252:DNA Mutational Analysis; D005784:Gene Amplification; D017353:Gene Deletion; D016147:Genes, Tumor Suppressor / Q000235:genetics*; D016158:Genes, p53 / Q000235:genetics*; D005909:Glioblastoma / Q000235:genetics*; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D008969:Molecular Sequence Data; D012150:Polymorphism, Restriction Fragment Length